Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20439712 | 0.86 | HTR2A (0.63) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL30645358 | 0.86 | HTR2A (0.63) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL1011034 | 0.86 | HTR2A (0.63) | MAOADRD2TSHRHSD17B10KDM4E | |
| Hydrochloric Acid SCHEMBL17674674 | 0.84 | HTR2A (0.61) | MAOADRD2TSHRHSD17B10KDM4E | |
| SCHEMBL2898828 | 0.81 | PNMT (0.56) | HTR2AHTR2CHTR2BKDM1APNMT | |
| SCHEMBL29396876 | 0.81 | PNMT (0.56) | HTR2AHTR2CHTR2BKDM1APNMT | |
| SCHEMBL6671284 | 0.81 | PNMT (0.56) | HTR2AHTR2CHTR2BKDM1APNMT | |
| Hydrochloric Acid SCHEMBL2895888 | 0.80 | PNMT (0.54) | HTR2AHTR2CHTR2BKDM1APNMT | |
| Hydrochloric Acid SCHEMBL31432788 | 0.80 | PNMT (0.54) | HTR2AHTR2CHTR2BKDM1APNMT | |
| SCHEMBL7820935 | 0.80 | MAOA (0.56) | MAOADRD2TSHRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| CN-119954773-A | PSMA compounds, pharmaceutical compositions comprising the same and uses thereof | 苏州威智创科生物有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025092841-A1 | PSMA COMPOUND, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 山东威智知科药业有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | MAOA 3498/4885DRD2 2749/4885TSHR 2279/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | MAOA 2172/4885DRD2 4641/4885TSHR 3734/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MAOA 1518/4885DRD2 3585/4885TSHR 1191/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | MAOA 2896/4885DRD2 133/4885TSHR 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.